1. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-48.
[CROSSREF] [PUBMED]
2. Faik Erdogan M, Gursoy A, Erdogan G, Kamel N. Radioactive iodine treatment in medullary thyroid carcinoma. Nucl Med Commun 2006;27:359-62.
[CROSSREF] [PUBMED]
3. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, et al. Postoperative radiotherapy for advanced medullary thyroid cancer: local disease control in the modern era. Head Neck 2008;30:883-8.
[CROSSREF] [PUBMED]
4. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25:567-610.
[CROSSREF] [PUBMED] [PMC]
5. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review 1975-2016, National Cancer Institute [Internet] Bethesda: SEER; 2019 [cited 2020 Oct 19]. Available from:
https://seer.cancer.gov/csr/1975_2016/.
6. Oh CM, Jung KW, Won YJ, Shin A, Kong HJ, Lee JS. Age-period-cohort analysis of thyroid cancer incidence in Korea. Cancer Res Treat 2015;47:362-9.
[CROSSREF] [PUBMED]
7. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 2017;317:1338-48.
[CROSSREF] [PUBMED] [PMC]
8. Sanabria A, Kowalski LP, Shah JP, Nixon IJ, Angelos P, Williams MD, et al. Growing incidence of thyroid carcinoma in recent years: factors underlying overdiagnosis. Head Neck 2018;40:855-66.
[CROSSREF] [PUBMED]
9. Park S, Oh CM, Cho H, Lee JY, Jung KW, Jun JK, et al. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ 2016;355:i5745.
[CROSSREF] [PUBMED] [PMC]
10. Randle RW, Balentine CJ, Leverson GE, Havlena JA, Sippel RS, Schneider DF, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017;161:137-46.
[CROSSREF] [PUBMED]
11. Ellison LF, Bushnik T. Changing trends in thyroid cancer incidence in Canada: a histologic examination, 1992 to 2016. Health Rep 2020;31:15-25.
[PUBMED]
12. Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI, et al. Trends in diagnostics, surgical treatment, and prognostic factors for outcomes in medullary thyroid carcinoma in Norway: a nationwide population-based study. Eur Thyroid J 2019;8:31-40.
[CROSSREF] [PUBMED]
13. Du L, Wang Y, Sun X, Li H, Geng X, Ge M, et al. Thyroid cancer: trends in incidence, mortality and clinical-pathological patterns in Zhejiang Province, Southeast China. BMC Cancer 2018;18:291.
[CROSSREF] [PUBMED] [PMC]
15. Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C. Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2008;69:497-505.
[CROSSREF] [PUBMED]
16. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42.
[CROSSREF] [PUBMED]
17. Choi YM, Kim TY, Jang EK, Kwon H, Jeon MJ, Kim WG, et al. Standardized thyroid cancer mortality in Korea between 1985 and 2010. Endocrinol Metab (Seoul) 2014;29:530-5.
[CROSSREF] [PUBMED] [PMC]
18. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015;136:2187-95.
[CROSSREF] [PUBMED]
19. Jung KY, Kim SM, Yoo WS, Kim BW, Lee YS, Kim KW, et al. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years. Clin Endocrinol (Oxf) 2016;84:587-97.
[CROSSREF] [PUBMED]
20. Kazaure HS, Roman SA, Sosa JA. Medullary thyroid microcarcinoma: a population-level analysis of 310 patients. Cancer 2012;118:620-7.
[CROSSREF] [PUBMED]
21. Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the national health information database of the national health insurance service in South Korea. Int J Epidemiol 2017;46:799-800.
[CROSSREF] [PUBMED]
22. World Health Organization. ICD-10 international statistical classification of diseases and related health problems: tenth revision; Gevena: World Health Organization; 2004.
23. Jung KY, Kim SM, Kim MJ, Cho SW, Kim BW, Lee YS, et al. Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea. Surgery 2018;164:312-8.
[CROSSREF] [PUBMED]
24. Kim BH. Registry for medullary thyroid carcinoma in Korea. In: 2015 Annual Symposium on Science, Technology, and Education & Autumn Symposium of KES; 2015 Oct 29-31; Busan, KR.
25. Jameson JL. Harrison’s principles of internal medicine; 20th ed. New York: McGraw Hill; 2018.
26. KOrean Statistical Information Service. Population statistics based on resident registration [Internet] Daejeon: KOSIS; 2020 [cited 2020 Oct 19]. Available from:
http://kosis.kr/index/index.do
.
28. Mathiesen JS, Kroustrup JP, Vestergaard P, Stochholm K, Poulsen PL, Rasmussen AK, et al. Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960-2014: a nationwide study. Endocr Connect 2018;7:829-39.
[CROSSREF] [PUBMED] [PMC]
29. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 1998;48:265-73.
[CROSSREF] [PUBMED]
30. Kim JH, Pyo JS, Cho WJ. Clinicopathological significance and prognosis of medullary thyroid microcarcinoma: a meta-analysis. World J Surg 2017;41:2551-8.
[CROSSREF] [PUBMED]
31. Hirsch D, Twito O, Levy S, Bachar G, Robenshtok E, Gross DJ, et al. Temporal trends in the presentation, treatment, and outcome of medullary thyroid carcinoma: an Israeli multicenter study. Thyroid 2018;28:369-76.
[CROSSREF] [PUBMED]
32. Cho BY, Choi HS, Park YJ, Lim JA, Ahn HY, Lee EK, et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid 2013;23:797-804.
[CROSSREF] [PUBMED] [PMC]
33. Choi JB, Lee SG, Kim MJ, Kim TH, Ban EJ, Lee CR, et al. Dynamic risk stratification in medullary thyroid carcinoma: single institution experiences. Medicine (Baltimore) 2018;97:e9686.
[CROSSREF] [PUBMED] [PMC]
34. Meijer JA, Bakker LE, Valk GD, de Herder WW, de Wilt JH, Netea-Maier RT, et al. Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. Eur J Endocrinol 2013;168:779-86.
[CROSSREF] [PUBMED]